Stivarga had already been approved in the treatment of colorectal tumors, but it was also approved for intestinal tract cancers on Monday.
A study to prove Stivarga’s effectiveness included approximately 200 patients who were broken into two groups—one group took Stivarga and the second group was given a placebo.
Findings showed that patients taking Stivarga, which blocks several enzymes that promote cancer growth, experienced a delay of up to 4-months in the growth of their cancer tumors versus those taking the placebo.
Although the drug has proven effective in treating intestinal tumors, Bayer recognizes a few side effects uncovered during trails—including liver damage, peeling of skin, high blood pressure, heart attacks, severe bleeding, blistering, and perforations.
Source: Vancouver Sun
